Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan–Amoxicillin dual therapy vs high-dose Omeprazole–Amoxicillin + Bismuth for first-line Helicobacter pylori eradication
TCTR20251120002Phase 4Recruiting
- Sponsor
- Department of Internal Medicine
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of vonoprazan, omeprazole, amoxicillin, bismuth subsalicylate in Helicobacter pylori infection, sponsored by Department of Internal Medicine. Started Jan 2025; status: recruiting.
02
Drugs
vonoprazanomeprazoleamoxicillinbismuth subsalicylate
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on TCTR20251120002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20251120002.